|
 |
TevetenThis page contains recent news articles, when available, and an overview of Teveten but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Teveten HCT is a combination medication used in the treatment of high blood pressure. One component, eprosartan, belongs to a class of blood pressure ... Free with registration - PDR Family Guide to Prescription Drugs - AccessMyLibrary.com Biovail profit down, stock up - Aug 5, 2005 Under the Kos deal, that company will take over Biovail's Teveten blood pressure drug and sell another blood pressure drug, Cardizem LA, ... CBC.ca Biovail sells off its US holdingsBiovail selling US operations; Buyer... - May 4, 2005 ...effort to restructure how it delivers products to general practitioners in the United States, means Biovail will hand over Teveten and Teveten HCT. ... Pay-Per-View - Toronto Star - ProQuest Archiver Kos Reports a 17% Increase in Revenue, Earnings Per Share of $0.71, … - Nov 9, 2006 Third quarter 2006 revenues for Kos' hypertension portfolio, comprised of Teveten(R), Teveten(R) HCT and Cardizem(R) LA totaled $35.7 million. ... Genetic Engineering News - Genetic Engineering News (press release) Teveten.(Drug overview) - Jan 22, 2007 Teveten is used to treat high blood pressure. It is a member of the family of drugs called angiotensin II receptor blockers. The hormone angiotensin II ... Free with registration - PDR Family Guide to Prescription Drugs - AccessMyLibrary.com Q1 2005 Kos Pharmaceuticals Earnings Conference Call - Final. - May 3, 2005 First, we are acquiring Teveten - an angiotensin II receptor blocker or ARB - and Teveten HCT, a product that combines Teveten with a diuretic, ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Teveten.(drug overview)(Drug overview) - Dec 1, 2005 Teveten is used to treat high blood pressure. It is a member of the family of drugs called angiotensin II receptor blockers. The hormone angiotensin II ... Free with registration - PDR Family Guide to Prescription Drugs - AccessMyLibrary.com Kos Reports Continued Double Digit Increase in Revenue, Financial … - Sep 5, 2006 Revenues for Kos' hypertension portfolio, comprised of Teveten(R),Teveten HCT and Cardizem(R)LA, totaled $31.6 million, excluding a $1.6million reduction in ... FINANZEN.NET NEWS - FINANZEN.NET NEWS … Pharmaceuticals Inc acquires BioVail Corp-Teveten Rights from... - May 3, 2005 CANADA - Kos Pharmaceuticals Inc agreed to acquire the Teveten Rights, a treatment for hypertension, from BioVail Corp, a manufacturer of pharmaceuticals, ... Pay-Per-View - deals - Alacra Store Kos Announces Presentation at the Citigroup 2006 Healthcare … - Feb 21, 2006 ...the treatment of asthma, Cardizem(R)LA for the treatment of hypertension and angina, and Teveten(R) and Teveten(R)HCT for the treatment of hypertension. ... Free with registration - Business Wire - AccessMyLibrary.com Kos Announces Presentation at the Deutsche Bank 2006 Healthcare … - Apr 25, 2006 ...the treatment of asthma, Cardizem(R)LA for the treatment of hypertension and angina, and Teveten(R) and Teveten(R)HCT for the treatment of hypertension. ... Genetic Engineering News - Genetic Engineering News (press release) Biovail Reports Fourth Quarter, Year-End 2004 Financial Results. - Mar 10, 2005 Revenues from Biovail's promoted products (Cardizem LA, Teveten, Teveten HCT, ... Biovail's Teveten franchise (Teveten, Teveten HCT) generated revenues of ... $4.95 - Business Wire - ECNext Kos Reports 49% Increase in Revenue to $179.4 Million, Earnings Per … - Aug 4, 2005 Kos recorded second quarter 2005 revenue for Teveten/ Teveten HCT of $4.8 million ... Teveten and Teveten HCT, products that possess an impressive clinical ... $4.95 - Business Wire - ECNext Biovail Reports Second-Quarter 2005 Financial Results. - Aug 4, 2005 As part of the agreement with Kos, Biovail divested the Teveten and Teveten HCT ... Accordingly, Biovail no longer has an economic interest in the Teveten ... $4.95 - Business Wire - ECNext Kos Pharmaceuticals at Bear Stearns 19th Annual Healthcare … - Sep 12, 2006 Our core products are Niaspan, a combination Niaspan with lovastatin called Advicor, Cardizem LA, Teveten and Teveten hydrochlorothiazide (HCT) and Azmacort ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com NEXIUM AMONG FIRST DRUGS TARGETED FOR HIGHER CO- … - Apr 2, 2005 The first two are likely to be Teveten, a heart medication with only 2200 ... But a majority disagreed with the committee's call to move Teveten off the ... $2.95 - Macon Telegraph - NewsBank Biovail Reports Second-Quarter 2006 Financial Results; Company … - Aug 10, 2006 ...associated with the sale of Teveten and Teveten HCT to Kos Pharmaceuticals, Inc., and a $4.9-million write-off of Cardizem(R) LA and Teveten inventories ... $4.95 - Business Wire - ECNext Kos Reports on Promising Data Presented at AHA: New Compound … - Nov 14, 2005 The Company currently markets Niaspan(R), Advicor(R), Azmacort(R), Cardizem(R)LA, Teveten(R), and Teveten(R)HCT. Kos has a strong and growing research and ... RedOrbit Article: Lange Makes Amends With TKO of Wilt - The Washington Post | ... - Oct 8, 2006 CRANBURY, N.J. -- Kos Pharmaceuticals, Inc. (Nasdaq: KOSP): --Kos to acquire Teveten(R), Teveten(R) HCT and obtain ... commercialization rights to ... Pay-Per-View - Washington Post - HighBeam Research Military Update: Two drugs likely to kick off co-pay hike - Apr 7, 2005 The first two are likely to be Teveten, a heart medication with only 2200 ... But a majority disagreed with the committee's call to move Teveten off the ... estripes.com Higher Co-Pays for Nexium? - Mar 31, 2005 The first two are likely to be Teveten, a heart medication with only 2200 ... But a majority disagreed with the committee's call to move Teveten off the ... Military.com Finance; Biovail reports revenues of $253 million - Sep 12, 2006 ...with the sale of Teveten and Teveten HCT to Kos Pharmaceuticals, Inc., ... write-off of Cardizem LA and Teveten inventories not purchased by Kos. ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Abbott Laboratories: Kos Pharmaceuticals a wise buy - Nov 8, 2006 Furthermore, with Kos having recently licensed a range of hypertensive treatments from the Biovail Corporation, namely Cardizem LA, Teveten and Teveten HCT ... Pharmaceutical Business Review Article: Prescribing chlorthalidone not as easy as ABC.(Cardiovascular... - Sep 15, 2007 Ernst. TEVETEN/HCTZ Clinical Trials More ... to-moderate high blood pressure participated in three ... DBP (systolic blood pressure over diastolic blood ... Pay-Per-View - Internal Medicine News - HighBeam Research Review to help trim drug costs - Apr 4, 2005 The first two are likely to be Teveten, a heart medication with only 2200 ... But a majority disagreed with the committee's call to move Teveten off the ... Honolulu Advertiser Article: Kenwood Bolsters CarPortal Lineup with New System Expansion ... - Jan 11, 2007 CRANBURY, N.J. -- Kos Pharmaceuticals, Inc. (Nasdaq: KOSP): --Kos to acquire Teveten(R), Teveten(R) HCT and obtain ... commercialization rights to ... Pay-Per-View - Wireless News - HighBeam Research <P>This article has been removed and is no longer available.</P> | … - May 3, 2005 Biovail's restructured approach to commercializing ... balance of 2005. As part of the agreement with Kos, Biovail divested the Teveten(R) and Teveten(R ... ... Pay-Per-View - Canadian Corporate News - HighBeam Research <P>This article has been removed and is no longer available.</P> | … - May 3, 2005 Biovail's restructured approach to commercializing ... balance of 2005. As part of the agreement with Kos, Biovail divested the Teveten(R) and Teveten(R ... ... Pay-Per-View - Canadian Corporate News - HighBeam Research Article: Box: Darchinyan makes winning return home - AAP Sports News... - Oct 20, 2007 CRANBURY, N.J. -- Kos Pharmaceuticals, Inc. (Nasdaq: KOSP): --Kos to acquire Teveten(R), Teveten(R) HCT and obtain ... commercialization rights to ... Pay-Per-View - AAP Sports News - HighBeam Research Article: Valuev vs. Barrett a King-sized bout: Adamek-Briggs added to... - Sep 1, 2006 CRANBURY, N.J. -- Kos Pharmaceuticals, Inc. (Nasdaq: KOSP): --Kos to acquire Teveten(R), Teveten(R) HCT and obtain ... commercialization rights to ... Pay-Per-View - Chicago Sun-Times - HighBeam Research Hypertension Classes of Medications - Hypertension Health Information... - Jul 15, 2008 Losartan (Cozaar, Hyzaar), olmesartan (Benicar) candesartan (Atacand), telmisartan (Micardis), eprosartan (Teveten), irbesartan (Avapro), and valsartan ... New York Times Biovail Reports Third-Quarter 2005 Financial Results - Nov 11, 2005 The Teveten line, divested in May 2005 to Kos, generated revenues of $6.5 million in the first ... Biovail no longer has an economic interest in Teveten. ... ccnmatthews.com Pharma's changing salesforces - Nov 8, 2005 Teveten competes against a triumvirate of heavyweights in the same class: ... Teveten, which has around 1% of the ARB market in the UK, is co-promoted with ... Pharmafocus SkyePharma and Kos Announce Exclusive Licence Agreement for … - May 8, 2006 ...treatment of asthma, Cardizem(R) LA for the treatment of hypertension and angina, and Teveten(R) and Teveten(R) HCT for the treatment of hypertension. ... Free with registration - PR Newswire - AccessMyLibrary.com Business & Finance; Pharma firm updates 2005 guidance - Jun 21, 2005 As a result of the sale of the Teveten products and the supply agreement for Cardizem LA with Kos Pharmaceuticals, Inc., Biovail is updating overall revenue ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Kos Pharmaceuticals Announces Compliance with NASDAQ Continued … - Sep 18, 2006 ...general corporate development activities. The Company currently markets Niaspan(R), Advicor(R), Azmacort(R), Cardizem(R)LA, Teveten(R) and Teveten(R)HCT. Free with registration - Business Wire - AccessMyLibrary.com Article: Reality show boxes into town - New Straits Times | HighBeam ... - Feb 27, 2005 CRANBURY, N.J. -- Kos Pharmaceuticals, Inc. (Nasdaq: KOSP): --Kos to acquire Teveten(R), Teveten(R) HCT and obtain ... commercialization rights to ... Pay-Per-View - New Straits Times - HighBeam Research ARBs might prevent, treat Alzheimer's - Jul 28, 2008 Merck has Cozaar, Boehringer Ingelheim has Micardis, Bristol-Myers Squibb and Sanofi-Aventis have Avapro, Kos has Teveten, and AstraZeneca has Atacand. ... FiercePharma Kos Announces Presentation at the Merrill Lynch Global Pharmaceutical,... - Feb 2, 2006 ...the treatment of asthma, Cardizem(R)LA for the treatment of hypertension and angina, and Teveten(R) and Teveten(R)HCT for the treatment of hypertension. ... Free with registration - Business Wire - AccessMyLibrary.com Kos Reports Summary Results From Clinical Study on Benefits of … - Jul 25, 2006 The Company currently markets Niaspan and Advicor(R), Azmacort(R), Cardizem(R)LA, and Teveten(R) and Teveten(R)HCT. Kos has a strong and growing research ... RedOrbit Kos Pharmaceuticals to Report First Quarter Results on May 9, 2006 … - May 9, 2006 ...the treatment of asthma, Cardizem(R)LA for the treatment of hypertension and angina, and Teveten(R) and Teveten(R)HCT for the treatment of hypertension. ... Genetic Engineering News - Genetic Engineering News (press release) Biovail Corporation Commences Offer to Purchase $56.6 Million of Its ... - May 25, 2006 The offer will be funded with the net proceeds resulting from the sale of Biovail's product rights and certain inventories related to Teveten and Teveten ... Free with registration - Business Wire - AccessMyLibrary.com Kos to Report Second Quarter Results on August 8, 2006 Conference … - Aug 8, 2006 The Company currently markets Niaspan(R), Advicor(R), Azmacort(R), Cardizem(R)LA, Teveten(R) and Teveten(R)HCT. Kos has a strong and growing research and ... businesswire.com Kos Pharmaceuticals To Report Third Quarter Results On November 3, … - Nov 3, 2005 ...for the treatment of asthma, Cardizem(R)LA for the treatment of hypertension and angina, Teveten(R) and Teveten(R)HCT for the treatment of hypertension. ... businesswire.com Kos and SkyePharma Sign Exclusive License Agreement for the … - Aug 5, 2006 ...treatment of asthma, Cardizem(R)LA for the treatment ofhypertension and angina, and Teveten(R) and Teveten(R)HCT for thetreatment of hypertension. ... Euro am Sonntag CORRECTING and REPLACING Kos Announces Presentation at the … - May 5, 2006 ...the treatment of asthma, Cardizem(R)LA for the treatment of hypertension and angina, and Teveten(R) and Teveten(R)HCT for the treatment of hypertension. ... Genetic Engineering News - Genetic Engineering News (press release) Kos to Report Third Quarter Results on November 9, 2006 Conference … - Nov 3, 2006 The Company currently markets Niaspan([R]), Advicor([R]), Azmacort([R]), Cardizem([R])LA, Teveten([R]) and Teveten([R])HCT. Free with registration - Business Wire - AccessMyLibrary.com Q2 2005 Kos Pharmaceuticals Earnings Conference Call - Final. - Aug 4, 2005 And secondly, the successful integration of the newly acquired cardiovascular products, Cardizem LA, Teveten, and Teveten HCT, which we purchased from ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com UP-OR-OUT RULES CAN CREATE HARDSHIPS ALL AROUND - May 8, 2005 Nexium and two other drugs --- Teveten and Teveten HCT, for high blood pressure --- are the first to be moved to non-formulary status, a new third tier of ... $2.95 - Macon Telegraph - NewsBank Medpace Adds Medical Director, Dr. Bernard E. Ilson, MD, FACP... - Dec 11, 2008 During his tenure with GSK, Dr. Ilson carried several drugs through fromearly phase development to regulatory approval and product launch,including Teveten ... International Business Times Kos to Present at the UBS Global Life Sciences Conference. - Sep 19, 2006 ...general corporate development activities. The Company currently markets Niaspan(R), Advicor(R), Azmacort(R), Cardizem(R)LA, Teveten(R) and Teveten(R)HCT. $4.95 - Business Wire - ECNext Kos Announces Presentation at the SG Cowen 26th Annual Health Care … - Feb 28, 2006 ...the treatment of asthma, Cardizem(R)LA for the treatment of hypertension and angina, and Teveten(R) and Teveten(R)HCT for the treatment of hypertension. ... $4.95 - Business Wire - ECNext Kos Appoints John J. Howarth as Vice President of Investor Relations... - Oct 19, 2005 ...treatment of asthma, Cardizem(R)LA for the treatment of hypertension and angina, and Teveten(R) and Teveten(R) HCT for the treatment of hypertension. ... $4.95 - Business Wire - ECNext Dishman to buy Solvay fine chemicals unit - Jul 9, 2007 Dishman currently supplies the API for Eprosartan Mesylate (EM) - a hypertensive drug marketed by Solvay under the brand Teveten - and its intermediates, ... In-PharmaTechnologist.com Arisaph Pharmaceuticals Announces Second Closing of $8 Million Equity... - Aug 9, 2006 The Company currently markets Niaspan(R), Advicor(R), Azmacort(R), Cardizem(R)LA, Teveten(R), and Teveten(R)HCT. Kos has a strong and growing research and ... $4.95 - PR Newswire - ECNext Kos Announces Annual Shareholders Meeting April 27, 2006. - Apr 19, 2006 ...the treatment of asthma, Cardizem(R)LA for the treatment of hypertension and angina, and Teveten(R) and Teveten(R)HCT for the treatment of hypertension. ... $4.95 - Business Wire - ECNext Drug/Medical Device - Dec 16, 2006 Teveten (Eprosartan Mesylate), Hypertension, Upper Respiratory Tract Infections, Rhinitis, ... Teveten HCT (Eprosartan/Hydrochlorothiazide), Hypertension ... $70.00 - Revere Reports - Revere Article: Briton in Athens court over drug trafficking; WOMAN, 23,... - Jun 9, 2005 CRANBURY, N.J. -- Kos Pharmaceuticals, Inc. (Nasdaq: KOSP): --Kos to acquire Teveten(R), Teveten(R) HCT and obtain ... commercialization rights to ... Pay-Per-View - Evening Standard - HighBeam Research Kos Pharmaceuticals to Report First Quarter Results on May 9, 2006 … - Apr 24, 2006 ...the treatment of asthma, Cardizem(R)LA for the treatment of hypertension and angina, and Teveten(R) and Teveten(R)HCT for the treatment of hypertension. ... $4.95 - Business Wire - ECNext Kos to Report Second Quarter Results on August 8, 2006 Conference … - Jul 27, 2006 The Company currently markets Niaspan(R), Advicor(R), Azmacort(R), Cardizem(R)LA, Teveten(R) and Teveten(R)HCT. Kos has a strong and growing research and ... $4.95 - Business Wire - ECNext Kos Pharmaceuticals to Report Second Quarter Results on August 4, … - Jul 6, 2005 ...for the treatment of asthma, Cardizem(R)LA for the treatment of hypertension and angina, Teveten(R) and Teveten(R)HCT for the treatment of hypertension. ... $4.95 - Business Wire - ECNext Article: 'THE LEGEND CONTINUES'; Thomas Hearns returns to ring, … - Jul 26, 2005 CRANBURY, N.J. -- Kos Pharmaceuticals, Inc. (Nasdaq: KOSP): --Kos to acquire Teveten(R), Teveten(R) HCT and obtain ... commercialization rights to ... Pay-Per-View - Michigan Chronicle - HighBeam Research Article: GOOSSENS TURN INTO A PAIR OF GYM RATS.(Sports) - Daily … - Aug 15, 2005 CRANBURY, N.J. -- Kos Pharmaceuticals, Inc. (Nasdaq: KOSP): --Kos to acquire Teveten(R), Teveten(R) HCT and obtain ... commercialization rights to ... Pay-Per-View - Daily News - HighBeam Research Article: At Ringside; Kronk Boxing returns to The Palace - Michigan … - May 3, 2005 CRANBURY, N.J. -- Kos Pharmaceuticals, Inc. (Nasdaq: KOSP): --Kos to acquire Teveten(R), Teveten(R) HCT and obtain ... commercialization rights to ... Pay-Per-View - Michigan Chronicle - HighBeam Research Article: At Ringside; Kronk Boxing back at The Palace - Michigan … - Nov 8, 2005 CRANBURY, N.J. -- Kos Pharmaceuticals, Inc. (Nasdaq: KOSP): --Kos to acquire Teveten(R), Teveten(R) HCT and obtain ... commercialization rights to ... Pay-Per-View - Michigan Chronicle - HighBeam Research Article: Drop in payout disappoints Bravo's trainer. - AZ Daily Star... - Sep 27, 2006 CRANBURY, N.J. -- Kos Pharmaceuticals, Inc. (Nasdaq: KOSP): --Kos to acquire Teveten(R), Teveten(R) HCT and obtain ... commercialization rights to ... Pay-Per-View - AZ Daily Star - HighBeam Research Kos Pharmaceuticals To Report Third Quarter Results On November 3, … - Oct 6, 2005 ...for the treatment of asthma, Cardizem(R)LA for the treatment of hypertension and angina, Teveten(R) and Teveten(R)HCT for the treatment of hypertension. ... $4.95 - Business Wire - ECNext Merger and Acquisition Scenario - Mar 11, 2006 Teveten HCT (Eprosartan/Hydrochlorothiazide). Calcium Channel Blocking Agents. Therapeutics that treat high blood pressure by blocking the beta adrenergic ... $250.00 - Revere Reports - Revere Company Profile Report - Dec 16, 2006 Teveten (Eprosartan Mesylate). Angiotensin II Receptor Antagonists/Thiazide Diuretic Agents. Products:. Teveten HCT (Eprosartan/Hydrochlorothiazide) ... $50.00 - Revere Reports - Revere Fenofibrate is Solvay Pharmaceuticals Flagship Product and Principal ... - Jan 12, 2007 ...(dronabinol) and Serc (betahistine); the influenza vaccine, Influvac; the pancreatic enzyme, Creon; and Teveten (eprosartan mesylate) for hypertension. ... Free with registration - M2 Presswire - AccessMyLibrary.com Press Release: SEMFF, SVYSY Have Also Been Removed From Naked … - Dec 29, 2008 It primarily offers TRICOR/LIPANTHYL and TEVETEN for cardiometabolics; ANDROGEL for men's health; CREON pancreatic enzymes; SERC and MARINOL for ... Pay-Per-View - M2 Presswire - HighBeam Research Minnesota - Official Notices - Department of Human Services - Jan 3, 2006 Teveten Angiotensin Receptor blocker-diuretic combinations Atacand HCT ... Teveten HCT ACE inhibitors Accupril Capoten Lotensin Mavik Monopril Prinivil ... Pay-Per-View - RegAlert - Factiva, from Dow Jones COMUNICADO: Abbott ampliará su presencia en el mercado de … - Nov 6, 2006 La compañÃa comercializa actualmente Niaspan, Advicor, Azmacort, Cardizem LA, Teveten y Teveten HCT. Kos tiene una lÃnea de proyecto sólida y cada vez mayor ... elEconomista.es Press Release: MEMY, MERR, TXPI, SVYSY Have Been Added To … - Dec 17, 2008 It primarily offers TRICOR/LIPANTHYL and TEVETEN for cardiometabolics; ANDROGEL for men's health; CREON pancreatic enzymes; SERC and MARINOL for ... Pay-Per-View - M2 Presswire - HighBeam Research 抗高血压è?¯ç‰©å¸‚场预测 - Jan 25, 2007 ...çš„olmesartan，以å?Šè´?æž—æ ¼å°”Â·å› æ ¼æµ·å§†ï¼?è‘›å…°ç´ Â·å…‹å…¬å?¸çš„替米沙 å?¦ï¼ˆMicardis，telmisartan），和Solvayå…¬å?¸çš„普沙å?¦ï¼ˆTeveten，eprosartan）将连ç»åœ¨ 新市场上市。 ... 金èž?ç•Œ Published at: www.reuters.com - Oct 29, 2007 My gut feeling is that much like Teveten and Ketek and even brand name Ziac, the market (we doctors) will drive whether or not GSK continues to manufacture ... Gerson Lehrman Group Pregnancy can bring risky type of high blood pressure - Dec 5, 2007 ...is taking an angiotension-coverting enzyme (ACE) inhibitor or angiotensin II receptor antagonists (examples: Lotensin; Capoten; Atacand or Teveten). ... Anderson Independent Mail Tamoxifen oder Toremifen (1904 mal gelesen) - Nov 2, 2008 Ich habe erhöhten Blutdruck nehme (Bisoborol, Teveten, Amlobesilat) und nach der Bestrahlung auf der einen Kopfseite ein Rauschen (es kann auch von ... Onmeda Expert on MRSA "Super Bug" Says New Science and Approach is … - Oct 18, 2007 ...on the development of such major pharmaceutical products as Lupron, Pravachol, Capoten, Kerlone, Cardene, Calan, Avandia, Actos, Teveten, and Atacand. ... newswise.com Solvay's sourcing from Dishman to cross Rs 100 cr. - Oct 23, 2006 Already, Solvay has increased sourcing of eprosartan, an API used in making anti-hypertensive drug Teveten, by 50 percent after their US foray. ... Free with registration - Economic Times - AccessMyLibrary.com High Blood Pressure Control is Equal with Common Medications - Nov 2, 2007 The ARBs included were candesartan cilexetil (Atacand), eprosartan (Teveten), irbesartan (Avapro), losartan (Cozaar), olmesartan medoxomil (Benicar), ... SeniorJournal.com Angiotensin II receptor blockers (ARBs) for high blood pressure - Apr 24, 2007 ...side effects (such as a cough) associated with ACE inhibitors. 1. Eprosartan mesylate (Teveten) is a recently approved ARB that is combined with a diuretic. MSN Health & Fitness Solvay's sourcing from Dishman to cross Rs 100 cr. | Article from … - Oct 23, 2006 Already, Solvay has increased sourcing of eprosartan, an API used in making anti-hypertensive drug Teveten, by 50 percent after their US foray. ... Pay-Per-View - Economic Times - HighBeam Research Biovail abolit 20% de ses effectifs - May 3, 2005 ...(BVF) procède à la suppression de 440 postes et vend les droits de distribution de son médicament pour l'hypertension, le Teveten, ainsi que les droits pour ... Canoë Biovail Reports First-Quarter 2006 Financial Results; Company Records... - May 11, 2006 ...as well as the May 2005 transaction with Kos Pharmaceuticals, Inc. (Kos), which included the divestiture of the Teveten line of products. ... Free with registration - Business Wire - AccessMyLibrary.com Biovail Reports Fourth Quarter, Year-End 2005 Financial Results - Mar 23, 2006 ...in Biovail Pharmaceuticals Canada (BPC) and Biovail's generics portfolio, as well as in Teveten revenues following the May 2005 transaction with Kos. ... ccnmatthews.com Angiotensin II receptor blockers (ARBs).(Cardiology Advisor 2007)(Drug... - May 31, 2007 Candesartan (Atacand), eprosartan (Teveten), irbesartan (Avapro), losartan (Cozaar), olmesartan (Benicar), telmisartan (Micardis), and valsartan (Diovan) ... $4.95 - Clinical Reference Systems - ECNext Solvay and Pronova Biocare sign license agreement for Omacor® to … - Sep 26, 2005 OMACOR® is part of the Solvay Pharmaceuticals' cardiology product portfolio, which also includes the anti-hypertensives, TEVETEN® (eprosartan), ... npicenter.com Event Brief of Q4 2004 Biovail Corporation Earnings Conference Call -... - Mar 10, 2005 While market share for Cardizem LA, Teveten, and Zovirax over the past six months has grown, it is clear that these product on their own will not enable BVF ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com PolyMedix Appoints Vice President of Clinical Development - Nov 8, 2006 Kerlone, Cardene, Calan, Avandia, Actos, Teveten, and Atacand. Dr. McAllister will be leading all of PolyMedix's clinical drug development efforts. ... Genetic Engineering News - Genetic Engineering News (press release) ARBs vs. ACE Inhibitors in Patients with Cardiac Disease - Sep 1, 2005 The studies used the following ARBs: losartan (Cozaar; n = 9), candesartan (Atacand; n = 7), valsartan (Diovan; n = 5), eprosartan (Teveten; n = 1), ... AAFP News Now Q2 2006 Kos Pharmaceuticals Earnings Conference Call - Part 2. - Aug 8, 2006 On Azmacort for the quarter, about 13%, and Teveten and Cardizem about 10%. ADRIAN ADAMS: And I would emphasize that if one looks at the comparative ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Event Brief of Q4 2005 Kos Pharmaceuticals Earnings Conference Call -... - Feb 23, 2006 As for the Teveten franchise, members of the fast-growing angiotensin-II receptor blocker class, total prescriptions grew 12% in 2005 vs. 2004. 7. ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Eplerenone (Systemic). - Oct 27, 2005 ...trandolapril [eg, Mavik]) or Angiotensin II receptor antagonists (Candesartan [eg, Atacand], eprosartan [eg, Teveten], irbesartan [eg, Avapro, Avalide], ... Free with registration - USP DI-Volume II, Advice for the... - AccessMyLibrary.com Q2 2005 Biovail Corporation Earnings Conference Call - Final. - Aug 4, 2005 As a result of this realignment we entered into a multi-faceted agreement with Kos Pharmaceuticals which included the divestiture of the Teveten line of ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Event Brief of Q2 2005 Biovail Corporation Earnings Conference Call -... - Aug 4, 2005 The Co. entered into a multifaceted agreement with Kos Pharmaceuticals which included the divestiture of the Teveten line of hypertension drugs and a ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Supplement update: Six to watch - Apr 18, 2006 Avapro, Cozaar, Micardis, Teveten). And there have been several published reports of people who suffered liver damage after drinking the juice. ... consumerreports.org Abstract and Introduction - Apr 29, 2005 Eprosartan (Teveten) and candesartan (Atacand) also can be dosed once or twice daily, but dos-ing decisions are up to physicians, who base such decisions on ... Medscape Protecting Your Kidneys - Aug 4, 2006 ...telmisartan (Micardis), and eprosartan (Teveten). These drugs appear to have a protective effect on kidneys above and beyond blood pressure control. ... Diabetes Self Management Chemical companies eye pharma pastures - Jan 15, 2006 ...when it signed an agreement with Netherlands-based Solvay Pharmaceuticals for sourcing eprosartan mesylate, an API for Teveten, a hypertensive drug. ... expresspharmapulse.com |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |